A VISIONaerie™ approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and... Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide... Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit...STOCK Quote
NASDAQ: AERI
$32.89USD
Jun 19, 4:00 PM ET
VOLUME
0
DAY LOW/HIGH
$32.59/$34.11
52 - WEEK LOW/HIGH
$31.01/$74.75
